Systematic Reviews of Treatments for Parkinson's Disease

Follow the links below to find summaries of systematic reviews of the evidence for the effectiveness of treatments for Parkinson's Disease.

Reviewed May 2012

34 Resources Found

Results 1 to 20 displayed.     1  2 

Title:   Cholinesterase inhibitors are beneficial for people with Parkinson's disease and dementia
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   The clinical features of dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD) have much in common. As patients with DLB and PDD have particularly severe deficits in cortical levels of the neurotransmitter acetylcholine, blocking i...
Date:   Aug 2011
Title:   [Coenzyme Q10 for Parkinson's Disease.]
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   [Mitochondrial dysfunction has been well established to occur in Parkinson's disease and appears to play a role in the pathogenesis of the disorder. A deficit in brain coenzyme Q10 status may be involved in the pathophysiology of Parkinson's disease. Mi...
Date:   Jul 2011
Title:   The effect of anti-inflammatory drugs in protecting the nerve cells involved in Parkinson's Disease
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Different agents have been examined for their effects in protecting the nerve cells that die in Parkinson's disease (PD). These are often called neuroprotective or disease-modifying agents. They can act by preventing the onset of the disease itself (cal...
Date:   May 2011
Title:   [Does eradication of the organism Helicobacter pylori from the gut of patients with Parkinson's disease improve the absorption of the main drug used to treat patients symptoms?]
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Helicobacter pylori (H pylori) is a common infection of the gut and is often associated with duodenal and gastric ulcers. The exact mechanism is unknown but there is some evidence that infection with H pylori can interfere with the absorption of some dr...
Date:   May 2011
Title:   The effect of blood pressure lowering drugs in protecting the nerve cells involved in Parkinson's disease
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Different agents have been examined for their effects in protecting the nerve cells that die in Parkinson's disease (PD). These agents are often called neuroprotective or disease modifying drugs. They can act by preventing the onset of the disease itsel...
Date:   May 2011
Title:   Speech and language therapy for speech problems in Parkinson's disease
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Many people with Parkinson's disease suffer from disorders of speech. The most frequently reported speech problems are weak, hoarse, nasal or monotonous voice, imprecise articulation, slow or fast speech, difficulty starting speech, impaired stress or r...
Date:   Apr 2011
Title:   Speech and language therapy for speech problems in Parkinson's disease
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Many people with Parkinson's disease suffer from disorders of speech. The most frequently reported speech problems are weak, hoarse, nasal or monotonous voice, imprecise articulation, slow or fast speech, difficulty starting speech, impaired stress or r...
Date:   Apr 2011
Title:   Physiotherapy for treatment of Parkinson's disease
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   In spite of various medical and surgical treatments for Parkinson's disease (PD), patients gradually develop significant physical problems. Physiotherapists aim to enable people with PD to maintain their maximum level of mobility, activity and independe...
Date:   Dec 2010
Title:   Treadmill training for people with Parkinson's disease
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   The role of treadmill training for people with Parkinson's disease in improving gait parameters is unclear. Gait hypokinesia is typically one of the primary movement disorders associated with Parkinson's disease. It is an important determinant of disabi...
Date:   Nov 2009
Title:   Drugs for motor complications in people with Parkinson's disease who are already taking levodopa
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   One of the complications of long-term treatment of Parkinson's disease (PD) with levodopa is the development of motor complications e.g. dyskinesia; a jerky, dance-like movement of the body. Generally clinicians add on drugs (to the levodopa regimen) fr...
Date:   Mar 2009
Title:   Monoamine oxidase B inhibitors compared with other treatments in early Parkinson's
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Many of the symptoms of Parkinson's disease are due to the loss of certain groups of nerves in the brain, which results in the lack of a chemical called dopamine. Currently, there are several different treatments available for people with newly diagnose...
Date:   Feb 2009
Title:   Dopamine agonist therapy in early Parkinson's disease
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   This 'umbrella' meta-analysis assesses dopamine agonists as a drug class in early Parkinson's disease. Twenty-nine eligible trials, involving 5247 participants, were identified. It confirms reports from individual trials that motor complications are red...
Date:   Jan 2008
Title:   Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Parkinson's disease is a disabling condition characterised by slowness of movement, trembling (tremors) and stiffness. Currently, the best treatment is levodopa. However, according to the number of levodopa treatment years, new disabling fluctuations of...
Date:   Aug 2007
Title:   Bromocriptine versus levodopa in early Parkinson's disease
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Parkinson's disease is a disabling disease characterised by slowness of movement, trembling (tremors) and stiffness. Currently, the best treatment for Parkinson's disease is levodopa. However, with the number of levodopa treatment years, new disabling f...
Date:   Aug 2007
Title:   There is inadequate evidence to evaluate the effect of occupational therapy for people with Parkinson's disease.
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Parkinson's disease is a progressive disabling neurodegenerative disease. Symptoms can include problems with movement such as being stiff, slow, and shaky, and sometimes non-motor symptoms such as problems with communication, mood, vision, and problem s...
Date:   May 2007
Title:   Insufficient data are available on the benefits of the COMT inhibitor tolcapone compared with the dopamine agonists bromocriptine and pergolide in relieving the symptoms of later Parkinson's disease.
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   As Parkinson's disease progresses the control of the symptoms often requires the addition of other drugs to levodopa. The principle aim of COMT inhibitor therapy is to increase the duration of effect of each levodopa dose and thus reduce the time patien...
Date:   Jun 2004
Title:   The COMT inhibitors entacapone and tolcapone show similar benefits in relieving levodopa-induced complications in Parkinson's disease but more data on the safety of tolcapone is required.
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   As Parkinson's disease progresses the control of the symptoms often requires the addition of other drugs to levodopa. The principle aim of COMT inhibitor therapy is to increase the duration of effect of each levodopa dose and thus reduce the time patien...
Date:   Jun 2004
Title:   Anti-depressant therapies may be able to help relieve depression in people with Parkinson's disease but more research is needed on safety and effectiveness.
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Parkinson's disease can lead to psychiatric as well as physical symptoms, the most common of which is depression. Oral antidepressants, electroconvulsive therapy or behavioural therapy are currently used in the treatment of depression in Parkinson's dis...
Date:   Feb 2003
Title:   There is not enough evidence about the safety and effectiveness of amantadine for people with dyskinesia in Parkinson's disease.
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Levodopa is regarded as the most effective treatment for Parkinson's disease but in many patients it causes abnormal involuntary movements known as dyskinesias. It is thought that amantadine may be added to levodopa to reduce dyskinesias in patients wit...
Date:   Jan 2003
Title:   Beta-blockers may be able to help relive tremor for people with Parkinson's disease, but more research is needed on safety and effectiveness.
Publisher:   John Wiley and Sons, Ltd. for The Cochrane Collaboration
Description:   Tremor is one of the main symptoms of Parkinson's disease, and it can be embarrassing and limit daily activities. The drugs most commonly used for Parkinson's disease tend to be more effective in treating other symptoms of the disease (such as rigidity ...
Date:   Sep 2002

Results 1 to 20 displayed.     1  2